ARWR as of Oct 31 · 17:00 ET
ARWRNasdaqPharmaceutical Preparations
Arrowhead Pharmaceuticals, Inc. · Brief
Next report
24 days
Nov 24 · after closeest.Q4 FY26
Expected move
Inputs3 of 8≥ implied
- avg implied
- ±10.1%
- avg realized
- ±9.3%
Nov 26 '24±12.1%▲+24.23%×2.00
Feb 10 '25±8.5%▼−5.17%×0.61
May 12 '25±9.0%▲+9.38%×1.04
Aug 7 '25±10.2%▲+2.24%×0.22
Nov 25 '25±13.6%▲+23.34%×1.71
Q1 FY26±11.4%▼−0.19%×0.02
Q2 FY26±7.3%▼−6.75%×0.93
Q3 FY26±8.5%▼−2.99%×0.35
quarterimplied−25%0+25%realized×
Q3 FY26±8.5%▼−2.99%×0.35
Q2 FY26±7.3%▼−6.75%×0.93
Q1 FY26±11.4%▼−0.19%×0.02
Nov '25±13.6%▲+23.34%×1.71
Aug '25±10.2%▲+2.24%×0.22
May '25±9.0%▲+9.38%×1.04
2 older reports
Feb '25±8.5%▼−5.17%×0.61
Nov '24±12.1%▲+24.23%×2.00
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close
Bull & bear
Nov 24 report · est.Bull2 of 4
Bear2 of 3
−6.18%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case
Linked exposure
ARWR report sessionCustomers 1
× = co-movement · max 500dSource: SEC filings · market data
No changes.
Your note
privateThesis 0 · Decisions 0 · Observations 0
No thesis.